Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205161 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT05205161 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 7 participants.
The verdict
NCT05205161, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This study evaluates the safety, tolerability, PK, and preliminary efficacy of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced NHL
Interventions
- DRUG AZD0466
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2023-08-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05205161
The ClinicalTrials.gov registry entry for NCT05205161 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD0466 is the first listed.
NCT05205161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05205161 about?
NCT05205161 is a clinical study titled "A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma". This study evaluates the safety, tolerability, PK, and preliminary efficacy of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced NHL
What is the current status of trial NCT05205161?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-07-05. Estimated completion is 2023-08-17.
What interventions are being tested in trial NCT05205161?
The interventions under investigation include: AZD0466 (DRUG).
Who is sponsoring clinical trial NCT05205161?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.